At the news
? BULLISHIMPACT 7/10 6-K filed Sep 14, 2026 at 08:28 ET
BioNTech and OncoC4 reported updated Phase 3 data for gotistobart in squamous NSCLC, showing median overall survival of 18.5 months vs 10.0 months for chemotherapy (HR 0.56, p=0.0295), nearly doubling survival. The data from stage 1 of the PRESERVE-003 trial is statistically significant but from a non-pivotal stage with only 87 patients, and the pivotal stage 2 is still ongoing. This is a meaningful clinical data update for a pipeline asset, but no revenue or earnings figures are reported, and the filing does not change the company's financial outlook.
- Gotistobart demonstrated median OS of 18.5 months vs 10.0 months for docetaxel (HR 0.56, nominal p=0.0295) in stage 1 of PRESERVE-003 Phase 3 trial
- Data cut-off July 17, 2026 with median follow-up of 25.4 months; 87 patients randomized (45 gotistobart, 42 docetaxel)
- Grade 3 treatment-related AEs: 44.4% gotistobart vs 48.8% docetaxel; safety profile manageable
- Pivotal stage 2 of PRESERVE-003 is ongoing at more than 160 sites globally
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access